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Disturbance of the circadian system, manifested as disrupted daily rhythms of physiologic
parameters such as sleep, activity, and hormone secretion, has long been observed as a
symptom of several neurodegenerative diseases, including Alzheimer disease. Circadian
abnormalities have generally been considered consequences of the neurodegeneration.
Recent evidence suggests, however, that circadian disruption might actually contribute to
the neurodegenerative process, and thus might be a modifiable cause of neural injury.
Herein we will review the evidence implicating circadian rhythms disturbances and clock
gene dysfunction in neurodegeneration, with an emphasis on future research directions
and potential therapeutic implications for neurodegenerative diseases.
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INTRODUCTION
Numerous studies over the past 30 years have described a wide
variety of circadian and sleep-wake cycle aberrations which occur
in aging and neurodegenerative diseases (Ju et al., 2014; Videnovic
et al., 2014a). Many behavioral and physiologic processes oscillate
with a 24 h period, including sleep–wake, activity, body temperature, blood pressure, and hormone secretion. These circadian
rhythms are frequently disrupted in patients with neurodegenerative disease, including Alzheimer disease (AD), Parkinson disease (PD), Huntington disease (HD). Systemic circadian rhythms
in mice and humans are maintained via the function of the
body’s master clock in the suprachiasmatic nucleus (SCN), which
receives input from the retina and synchronizes oscillations in
peripheral organs to the light:dark cycle. On a cellular level, circadian rhythms are generated by a transcriptional–translational
feedback loop consisting of the bHLH/PAS transcription factors
BMAL1 and CLOCK, which heterodimerize and drive transcription of many genes, including their own negative feedback repressors, including PERIOD (Per) and CRYPTOCHROME (Cry) and
REVERB genes, which repress BMAL1/CLOCK-mediated transcription (Mohawk et al., 2012). This transcriptional machinery,
which we will refer to herein as the core circadian clock, is present
in most cells in the body, including neurons and astrocytes in the
SCN and throughout the brain. The core circadian clock regulates
the circadian expression of thousands of genes in a tissue-specific
manner, and is a major regulator of cellular metabolism, stress
response, and many other functions (Bass and Takahashi, 2010;
Evans and Davidson, 2013). While whole-organism rhythms are
known to be disrupted in many neurodegenerative diseases, far
less information exists regarding specific alterations in clock protein expression and function in these conditions. Furthermore, it
remains unclear if or how circadian disruption might influence
the neurodegenerative process itself, or if the core clock represents
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a reasonable therapeutic target for the treatment or prevention
of neurodegeneration. We will focus on these issues in this
review.

PART 1: IS THERE EVIDENCE OF CORE CIRCADIAN CLOCK
DYSFUNCTION IN NEURODEGENERATIVE DISEASES?
In AD, both sleep and circadian dysfunction are commonly
reported. While sleep disturbances in AD are beyond the scope of
this discussion and have been reviewed elsewhere (Ju et al., 2014;
Peter-Derex et al., 2014), it is important to mention that subtle
sleep disturbances appear to occur early in the disease process
and may predict amyloid-beta (Aβ) plaque pathology and precede
subsequent development of clinical dementia (Ju et al., 2013; Lim
et al., 2013a; Spira et al., 2013). Disrupted circadian rhythms in
activity, physiologic parameters, and melatonin secretion have
been reported in AD reported by several groups (Witting et al.,
1990; Skene and Swaab, 2003; Hatfield et al., 2004; Wu et al., 2006;
Hu et al., 2009; Coogan et al., 2013). A proposed mechanism
of circadian dysfunction in AD is degeneration of the SCN,
as loss of critical vasopressin and vasoactive intestinal peptide
(VIP)-expressing neurons in this region has been reported in AD
patients (Swaab et al., 1985; Zhou et al., 1995; Farajnia et al.,
2012). Transcriptional analysis of postmortem human brain tissue
has revealed detectable oscillations in core clock genes in various
brain regions based on time of death, and shown that in AD
brains the phase of oscillation is dysregulated between various
regions (Cermakian et al., 2011; Lim et al., 2013b). Rhythms in
whole-genome DNA methylation could also be detected which
appear to become less robust with age or in AD brains (Lim et al.,
2014). Circadian oscillation of clock genes in the human pineal
gland was disrupted even at very early pathological stages of AD,
mirroring loss of rhythmic melatonin secretion in AD patients
(Skene and Swaab, 2003; Wu et al., 2006). Thus, in human AD
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there is evidence of disturbed rhythms of clock gene expression
which appear to begin early in the disease course.
Animal models of AD also exhibit disturbances of behavioral
and physiologic circadian rhythms. In mice, these disturbances
appear to correlate with the degree of amyloid plaque burden,
and can in some cases be rescued with anti-Aβ immunotherapy, suggesting that aggregated forms of Aβ might disrupt clock
mechanisms (Wisor et al., 2005; Sterniczuk et al., 2010; Duncan
et al., 2012; Roh et al., 2012). However, while one study described
damped expression of Per2 in the SCN of APP-PS1 transgenic
mice (Duncan et al., 2012), more detailed molecular analysis of
clock gene function in AD mouse models is lacking. In Drosophila,
two groups have found that pan-neuronal expression of arctic
mutant human Aβ causes marked degradation of behavioral
circadian rhythms, despite preserved clock gene oscillation in the
central pacemaker cells (Chen et al., 2014; Long et al., 2014). Chen
et al. (2014) found that restricted Aβ expression in central clock
(PDF) neurons did not disrupt clock gene oscillation or cause
behavioral arrhythmicity, which Aβ expression in glia surrounding the clock neurons did both. Thus, in flies, Aβ does not directly
disrupt clock gene function in the central pacemaker, but acts
more peripherally (and perhaps on glia) to disrupt behavioral
rhythms. While the biological relevance of this fly models of Aβ
toxicity to humans is debatable, these findings provide leads for
further research in mammalian models.
In the case of PD, the second most common age-related
neurodegenerative condition, there is ample evidence of disrupted
circadian rhythms and sleep–wake disturbance in humans and
mouse models (Videnovic and Golombek, 2013). PD patients
exhibit progressive disruption of activity rhythms (Niwa et al.,
2011), as well as damped circadian oscillation of both melatonin
release and Bmal1 expression in peripheral blood monocytes
(Cai et al., 2010; Breen et al., 2014; Videnovic et al., 2014b).
Fly and mouse models of PD which expresses mutant human
α-synuclein, a protein implicated in PD pathogenesis, develop
behavioral circadian disruption early in its disease course (Gajula
Balija et al., 2011; Kudo et al., 2011a). Synuclein transgenic mice
display normal Per2 oscillation in the SCN, but have damped
electrical output from the SCN, again suggesting disordered SCN
function or synchrony (Kudo et al., 2011a).
Huntington disease, unlike AD and PD, is an autosomal disorder caused by trinucleotide expansion within the huntingtin gene.
Neurodegeneration occurs earlier in HD patients and initially
involves the basal ganglia. Sleep and circadian rhythm dysfunction
are common in HD (Morton et al., 2005; Aziz et al., 2010), though
there is a paucity of studies on clock gene expression and function
in human HD. Several mouse models of HD, which express
expanded human huntingtin, develop pronounced impairment in
behavioral circadian rhythms (Morton et al., 2005; Kudo et al.,
2011b). The R6/2 line exhibits behavioral arrhythmicity as well as
dysregulated clock gene oscillation in vivo in the liver and SCN
(Morton et al., 2005; Maywood et al., 2010). Interestingly, clock
gene oscillation appears to be normal in liver or SCN explants
from R6/2 mice, suggesting that some other aspect of the internal
milieu of the R6/2 mouse is causing arrhythmicity in vivo (Pallier
et al., 2007; Maywood et al., 2010). In another HD mouse line
(BACHD) the rhythmicity of electrical output of the SCN was
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disrupted, while the oscillation of Per2 transcription was grossly
intact (Kudo et al., 2011b). These findings suggest support the
idea that dysfunction of the neural networks within the SCN,
rather than the cell-intrinsic clock gene oscillation, underlies
circadian impairment in HD model mice. Accordingly, decreased
expression of the neuropeptide VIP and the VIP receptor VPAC2,
which are critical for SCN function (Aton et al., 2005), was also
observed in R6/2 mice (Fahrenkrug et al., 2007). It appears that
in HD mice, disrupted peripheral rhythms may adversely impact
SCN function, leading to further systemic circadian arrhythmicity, though the details of this mechanism are still being
explored.

PART 2: IS THERE EVIDENCE THAT CLOCK DISRUPTION
EXACERBATES NEURODEGENERATION?
While circadian disturbances in aging and neurodegenerative
diseases have been duly noted, a key question is whether these
disturbances influence disease pathology. This question is much
more difficult to examine, and has received significantly less
attention. In Drosophila, levels of oxidative stress markers, as well
as cellular content of the critical antioxidant glutathione show
circadian oscillation which is dependent on the clock gene Period
(Per, Krishnan et al., 2008; Beaver et al., 2012). Per deletion
exacerbates oxidative injury and shortens lifespan in Drosophila
(Krishnan et al., 2008, 2009). Disruption of clock function via
Per deletion also accelerates neurodegeneration in flies bearing
a carbonyl reductase mutation which causes oxidative injury
to neurons (Krishnan et al., 2012). However, in fly models of
Aβ pathology which express different human Aβ isoforms, Per
deletion did not impact neurodegeneration or behavior, though
lifespan was decreased. Conversely, levels of Cryptochrome (Cry),
which serves as a light-responsive modulator of clock function in
Drosophila, decline in parallel with damped circadian rhythms in
old flies, while Cry overexpression restores robust rhythms and
enhances lifespan (Rakshit and Giebultowicz, 2013). Thus, the
clock genes Per and Cry clearly appear to contribute to regulation
of brain aging and neurodegeneration in fly models.
In mice, evidence linking circadian dysfunction and neurodegeneration is emerging. Chronic disruption of circadian
rhythms in mice via housing in 20:4 light:dark conditions leads to
decreased neuronal dendritic arborization and cognitive deficits,
demonstrating that disturbed circadian rhythms have negative
implications for the brain, though the exact degree of clock
gene dysregulation and the role of other factors such as stress
are unknown (Karatsoreos et al., 2011). Accordingly, studies
in rats and hamsters have demonstrated cognitive impairment
and decreased hippocampal neurogenesis following chronic “jet
lag” protocols, during which circadian rhythms are disrupted
by frequent shifting of the light:dark cycle (Gibson et al., 2010;
Kott et al., 2012). Mechanistically, RevErbα-mediated regulation
of fatty acid binding protein 7 (Fabp7), both of which are strongly
controlled by the core clock, has been implicated in neurogenesis
(Schnell et al., 2014). Similarly, RevErbα shows dynamic activitydependent regulation in the dendrites of hippocampal neurons
and interacts with oligophrenin-1, a regulator of dendritic spines
(Valnegri et al., 2011). In a mouse model of AD, Aβ levels in
the brain interstitial fluid show pronounced circadian oscillation
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(Kang et al., 2009), though it unclear if this is a direct effect of the
sleep–wake cycle or may be more directly clock-mediated.
In order to gain some appreciation of the role of clock genes in
maintaining brain homeostasis, our group performed functional
and neuropathologic analysis of mice with global deletion of
Bmal1. Bmal1 knockout (KO) mice developed marked astrogliosis
which was evident by 2 months of age and progressed to involve
the entirety of the cortex, striatum, and hippocampus (Musiek
et al., 2013). These mice also had increased levels of oxidative
damage in the cortex, and exhibited spontaneous degeneration
of presynaptic terminals and diminished cortical functional connectivity. We found a similar phenotype in Clock;Npas2 double
KO mice, which like Bmal1 KOs have completely disabled core
clock transcriptional function (DeBruyne et al., 2007), but not
in Per1/Per2 double mutant mice, which are arrhythmic but
have intact core clock-mediated transcription (Bae et al., 2001).
We subsequently generated brain-specific Bmal1 KO mice which
have preserved SCN Bmal1 expression and intact systemic circadian activity and sleep rhythms, but disrupted BMAL1-mediated
transcription in cortical, striatal, and hippocampal neurons and
astrocytes. These mice also developed severe astrogliosis, suggesting that positive-limb core clock function is required locally
in neurons and/or astrocytes to prevent pathology, independent
of the SCN or sleep–wake cycle (Musiek et al., 2013). Finally,
we found that neurodegeneration induced by the mitochondrial
complex II inhibitor 3-nitropropionic acid, which has been used
to model HD (Beal et al., 1995), was exacerbated in Bmal1
hemizygous mice, which have intact systemic rhythms but only
half the normal level of BMAL1 protein expression in the brain.
Thus, it appears that the core clock transcriptional machinery
plays a critical role in protecting the brain from oxidative injury,
and that this function is not entirely dictated by systemic circadian
rhythms. Accordingly, we found that Bmal1 directly regulates
the transcription of several important redox defense genes in
the brain, including Nqo1 and Aldh2. We are currently working
to identify novel mechanisms by which the core clock mediates
neuroprotection or neurodegeneration, and to understand the
relative importance of systemic circadian rhythms and clock
gene oscillation versus static transcriptional function in this
process.
Conversely, the effect of improving circadian function on
pathology in a mouse model of neurologic disease has been
demonstrated, at least initially. In the aforementioned R6/2 mouse
model of HD, pharmacologic induction of rhythmic sleep normalized Per2 oscillation in the SCN and lead to improvements
in cognition (Pallier et al., 2007; Pallier and Morton, 2009).
Furthermore, when food was provided to these mice only during
a strategic window in the circadian cycle, rhythms in behavior were restored and metabolic abnormalities in these mice
improved, suggesting that synchronizing the food-entrainable
oscillator could overcome the circadian defect. Thus, correcting
peripheral rhythms by imposing circadian sleep or feeding schedules can mitigate cognitive impairment in a mouse model of
HD (Maywood et al., 2010). The application of these methods,
or more specific molecular targeting of the core clock or its
outputs, now needs to be evaluated in other animal models of
neurodegeneration.
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Human data demonstrating a contributory effect of circadian
disruption to neurodegeneration is scarce, though several encouraging findings have emerged. Two observational studies examining young female flight attendants who routinely flew across
multiple time zones found that the group that those afforded
shorter recovery time between cross-time zone flights (who thus
experienced more severe circadian disruption) had higher cortisol
levels, smaller temporal lobe volumes on MRI, and performed
more poorly on hippocampal-based cognitive testing than ground
crew members or other flight attendants with less severe jet lag
exposure (Cho et al., 2000; Cho, 2001). In the field of AD, a small
amount of human data now also exists which supports a role
for circadian disruption in disease pathogenesis. Three separate
genetic polymorphism in the Clock gene have been linked to
increased risk of AD in Han Chinese populations (Chen et al.,
2013a,b; Yang et al., 2013), though these findings have not been
reported by other large AD genetics consortiums. An epidemiologic study of daily activity data from of over 1,200 initially
cognitively-normal older women demonstrated that diminished
circadian rhythm amplitude, robustness, or phase delay were
associated with increased risk of developing dementia during
the 5 year follow-up period (Tranah et al., 2011). On a more
mechanistic level, circadian oscillations in the level of the Aβ in
cerebrospinal fluid of older adults has been described and suggest
possible regulation of Aβ metabolism by the circadian clock,
though it does not demonstrate a clear role for these oscillations
in the disease process (Kang et al., 2009; Huang et al., 2012).
Further research into circadian function in prodromal AD and
other neurodegenerative disease, and how this relates to disease
risk or progression is needed.

CONCLUSIONS AND THERAPEUTIC PERSPECTIVES
Taken in total, there is promising early data but not iron-clad
proof that circadian clock disruption contributes to the pathogenesis of age-related neurodegenerative diseases. Two major challenges in this area are apparent. First, distinguishing the specific
effects of alterations in sleep from those of the circadian clock
is difficult but necessary. Activity data (actigraphy) in humans
is often used as a biomarker of sleep or circadian rhythms, and
the two processes are often lumped together, obscuring specific
conclusions about either. Of further concern is the fact that
disrupting sleep impacts core clock protein function (Mongrain
et al., 2011), while deleting clock genes also alters sleep (Laposky
et al., 2005). Disentangling these two processes is important if we
hope to identify specific downstream pharmacologic targets from
either pathway to treat or prevent neurodegenerative diseases.
The second major challenge involves distinguishing the specific importance of circadian oscillation versus the “static” function of clock proteins in the brain. While circadian oscillations
are observed in thousands of transcripts in many tissues, including the brain, the physiological relevance of these oscillations
remains in many cases unclear (Zhang et al., 2014). Clock proteins
exert various functions in cells, some of which may have less
dependence on these oscillations. Ultimately, the function of clock
proteins is never completely disengaged from their oscillation, as
the BMAL1/CLOCK DNA binding shows clear circadian variation
(Koike et al., 2012), but the relative importance of rhythmic versus
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static function remains a key therapeutic question. If restoration
of robust systemic oscillations is the therapeutic goal, then therapies might target the SCN. Vasopressin V1a and V1b, as well as
VIP VPAC2 receptors, play critical roles in synchronizing SCN
neurons and their response to phase shift, and thus might represent tractable therapeutic targets to optimize systemic rhythms
(Aton et al., 2005; An et al., 2013; Kudo et al., 2013; Yamaguchi
et al., 2013). Behavioral manipulations such as imposed light:dark
exposure, timed melatonin treatment, or rhythmic meal schedules
might have shown promise in HD mouse models and might also
be considered (Pallier et al., 2007; Maywood et al., 2010). Finally,
novel small molecule modulators of clock oscillation are being
developed which alter the period, amplitude, or frequency of
SCN output (Hirota et al., 2010; Chen et al., 2012). However,
if bolstering clock gene expression outside the SCN is the more
advantageous strategy, then a new set of therapies would need to
be developed. In this case, downstream neuroprotective targets of
the core clock would need to be identified and screening pursued
to identify compounds or strategies which enhance core clock
transcription of these protective downstream targets. Because
the clock serves as an orchestrator of a multitude of biological
processes, there is great potential for clock-targeted therapeutics to simultaneously ameliorate multiple pathologic aspects of
complex neurodegenerative diseases. Thus, it is important to
more fully understand the mechanisms by which the circadian
clock regulates brain function and neurodegeneration, such that
rational strategies to target the clock for neuroprotection can be
devised.

ACKNOWLEDGMENTS
ESM acknowledges funding from NIH grant K08NS079405
(ESM); Alzheimer’s Association grant NIRP-14-305476 (ESM),
and Donor’s Cure Foundation (ESM).
REFERENCES
An, S., Harang, R., Meeker, K., Granados-Fuentes, D., Tsai, C. A., Mazuski, C., et al.
(2013). A neuropeptide speeds circadian entrainment by reducing intercellular
synchrony. Proc. Natl. Acad. Sci. U.S.A. 110, E4355–E4361. doi: 10.1073/pnas.
1307088110
Aton, S. J., Colwell, C. S., Harmar, A. J., Waschek, J., and Herzog, E. D. (2005).
Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony
in mammalian clock neurons. Nat. Neurosci. 8, 476–483. doi: 10.1038/nn1419
Aziz, N. A., Anguelova, G. V., Marinus, J., Lammers, G. J., and Roos, R. A. (2010).
Sleep and circadian rhythm alterations correlate with depression and cognitive
impairment in Huntington’s disease. Parkinsonism Relat. Disord. 16, 345–350.
doi: 10.1016/j.parkreldis.2010.02.009
Bae, K., Jin, X., Maywood, E. S., Hastings, M. H., Reppert, S. M., and Weaver, D. R.
(2001). Differential functions of mPer1, mPer2, and mPer3 in the SCN circadian
clock. Neuron 30, 525–536. doi: 10.1016/S0896-6273(01)00302-6
Bass, J., and Takahashi, J. S. (2010). Circadian integration of metabolism and
energetics. Science 330, 1349–1354. doi: 10.1126/science.1195027
Beal, M. F., Ferrante, R. J., Henshaw, R., Matthews, R. T., Chan, P. H., Kowall, N. W.,
et al. (1995). 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc
superoxide dismutase transgenic mice. J. Neurochem. 65, 919–922. doi: 10.1046/
j.1471-4159.1995.65020919.x
Beaver, L. M., Klichko, V. I., Chow, E. S., Kotwica-Rolinska, J., Williamson, M.,
Orr, W. C., et al. (2012). Circadian regulation of glutathione levels and biosynthesis in Drosophila melanogaster. PLoS ONE 7:e50454. doi: 10.1371/journal.
pone.0050454
Breen, D. P., Vuono, R., Nawarathna, U., Fisher, K., Shneerson, J. M., Reddy, A. B.,
et al. (2014). Sleep and circadian rhythm regulation in early Parkinson disease.
JAMA Neurol. 71, 589–595. doi: 10.1001/jamaneurol.2014.65

Circadian clocks and neurodegeneration

Cai, Y., Liu, S., Sothern, R. B., Xu, S., and Chan, P. (2010). Expression of clock
genes Per1 and Bmal1 in total leukocytes in health and Parkinson’s disease. Eur.
J. Neurol. 17, 550–554. doi: 10.1111/j.1468-1331.2009.02848.x
Cermakian, N., Lamont, E. W., Boudreau, P., and Boivin, D. B. (2011). Circadian
clock gene expression in brain regions of Alzheimer’s disease patients and
control subjects. J. Biol. Rhythms 26, 160–170. doi: 10.1177/0748730410395732
Chen, H. F., Huang, C. Q., You, C., Wang, Z. R., and Si-Qing, H. (2013a). Polymorphism of CLOCK gene rs 4580704 C > G is associated with susceptibility of
Alzheimer’s disease in a Chinese population. Arch. Med. Res. 44, 203–207. doi:
10.1016/j.arcmed.2013.01.002
Chen, Q., Huang, C. Q., Hu, X. Y., Li, S. B., and Zhang, X. M. (2013b). Functional
CLOCK gene rs1554483 G/C polymorphism is associated with susceptibility to
Alzheimer’s disease in the Chinese population. J. Int. Med. Res. 41, 340–346. doi:
10.1177/0300060513476430
Chen, K. F., Possidente, B., Lomas, D. A., and Crowther, D. C. (2014). The central
molecular clock is robust in the face of behavioural arrhythmia in a Drosophila
model of Alzheimer’s disease. Dis. Model. Mech. 7, 445–458. doi: 10.1242/dmm.
014134
Chen, Z., Yoo, S. H., Park, Y. S., Kim, K. H., Wei, S., Buhr, E., et al. (2012).
Identification of diverse modulators of central and peripheral circadian clocks
by high-throughput chemical screening. Proc. Natl. Acad. Sci. U.S.A. 109, 101–
106. doi: 10.1073/pnas.1118034108
Cho, K. (2001). Chronic ‘jet lag’ produces temporal lobe atrophy and spatial
cognitive deficits. Nat. Neurosci. 4, 567–568. doi: 10.1038/88384
Cho, K., Ennaceur, A., Cole, J. C., and Suh, C. K. (2000). Chronic jet lag produces
cognitive deficits. J. Neurosci. 20, 1–5.
Coogan, A. N., Schutova, B., Husung, S., Furczyk, K., Baune, B. T., Kropp, P.,
et al. (2013). The circadian system in Alzheimer’s disease: disturbances, mechanisms, and opportunities. Biol. Psychiatry 74, 333–339. doi: 10.1016/j.biopsych.
2012.11.021
DeBruyne, J. P., Weaver, D. R., and Reppert, S. M. (2007). CLOCK and NPAS2 have
overlapping roles in the suprachiasmatic circadian clock. Nat. Neurosci. 10, 543–
545. doi: 10.1038/nn1884
Duncan, M. J., Smith, J. T., Franklin, K. M., Beckett, T. L., Murphy, M. P., St Clair,
D. K., et al. (2012). Effects of aging and genotype on circadian rhythms,
sleep, and clock gene expression in APPxPS1 knock-in mice, a model for
Alzheimer’s disease. Exp. Neurol. 236, 249–258. doi: 10.1016/j.expneurol.2012.
05.011
Evans, J. A., and Davidson, A. J. (2013). Health consequences of circadian disruption in humans and animal models. Prog. Mol. Biol. Transl. Sci. 119, 283–323.
doi: 10.1016/B978-0-12-396971-2.00010-5
Fahrenkrug, J., Popovic, N., Georg, B., Brundin, P., and Hannibal, J. (2007).
Decreased VIP and VPAC2 receptor expression in the biological clock of the
R6/2 Huntington’s disease mouse. J. Mol. Neurosci. 31, 139–148. doi: 10.1385/
JMN/31:02:139
Farajnia, S., Michel, S., Deboer, T., Vanderleest, H. T., Houben, T., Rohling, J. H.,
et al. (2012). Evidence for neuronal desynchrony in the aged suprachiasmatic
nucleus clock. J. Neurosci. 32, 5891–5899. doi: 10.1523/JNEUROSCI.0469-12.
2012
Gajula Balija, M. B., Griesinger, C., Herzig, A., Zweckstetter, M., and Jackle, H.
(2011). Pre-fibrillar α-synuclein mutants cause Parkinson’s disease-like nonmotor symptoms in Drosophila. PLoS ONE 6:e24701. doi: 10.1371/journal.pone.
0024701
Gibson, E. M., Wang, C., Tjho, S., Khattar, N., and Kriegsfeld, L. J. (2010).
Experimental ‘jet lag’ inhibits adult neurogenesis and produces long-term
cognitive deficits in female hamsters. PLoS ONE 5:e15267. doi: 10.1371/journal.
pone.0015267
Hatfield, C. F., Herbert, J., Van Someren, E. J., Hodges, J. R., and Hastings, M. H.
(2004). Disrupted daily activity/rest cycles in relation to daily cortisol rhythms
of home-dwelling patients with early Alzheimer’s dementia. Brain 127, 1061–
1074. doi: 10.1093/brain/awh129
Hirota, T., Lee, J. W., Lewis, W. G., Zhang, E. E., Breton, G., Liu, X., et al. (2010).
High-throughput chemical screen identifies a novel potent modulator of cellular
circadian rhythms and reveals CKIα as a clock regulatory kinase. PLoS Biol.
8:e1000559. doi: 10.1371/journal.pbio.1000559
Hu, K., Van Someren, E. J., Shea, S. A., and Scheer, F. A. (2009). Reduction of
scale invariance of activity fluctuations with aging and Alzheimer’s disease:
involvement of the circadian pacemaker. Proc. Natl. Acad. Sci. U.S.A. 106, 2490–
2494. doi: 10.1073/pnas.0806087106

Frontiers in Pharmacology | Pharmaceutical Medicine and Outcomes Research

February 2015 | Volume 6 | Article 29 | 4

Musiek

Huang, Y., Potter, R., Sigurdson, W., Santacruz, A., Shih, S., Ju, Y. E., et al. (2012).
Effects of age and amyloid deposition on Aβ dynamics in the human central
nervous system. Arch. Neurol. 69, 51–58. doi: 10.1001/archneurol.2011.235
Ju, Y. E., Lucey, B. P., and Holtzman, D. M. (2014). Sleep and Alzheimer disease
pathology—a bidirectional relationship. Nat. Rev. Neurol. 10, 115–119. doi:
10.1038/nrneurol.2013.269
Ju, Y. E., Mcleland, J. S., Toedebusch, C. D., Xiong, C., Fagan, A. M., Duntley, S. P.,
et al. (2013). Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 70,
587–593. doi: 10.1001/jamaneurol.2013.2334
Kang, J. E., Lim, M. M., Bateman, R. J., Lee, J. J., Smyth, L. P., Cirrito, J. R., et al.
(2009). Amyloid-β dynamics are regulated by orexin and the sleep–wake cycle.
Science 326, 1005–1007. doi: 10.1126/science.1180962
Karatsoreos, I. N., Bhagat, S., Bloss, E. B., Morrison, J. H., and Mcewen, B. S.
(2011). Disruption of circadian clocks has ramifications for metabolism, brain,
and behavior. Proc. Natl. Acad. Sci. U.S.A. 108, 1657–1662. doi: 10.1073/pnas.
1018375108
Koike, N., Yoo, S. H., Huang, H. C., Kumar, V., Lee, C., Kim, T. K., et al. (2012).
Transcriptional architecture and chromatin landscape of the core circadian clock
in mammals. Science 338, 349–354. doi: 10.1126/science.1226339
Kott, J., Leach, G., and Yan, L. (2012). Direction-dependent effects of chronic
“jet-lag” on hippocampal neurogenesis. Neurosci. Lett. 515, 177–180. doi:
10.1016/j.neulet.2012.03.048
Krishnan, N., Davis, A. J., and Giebultowicz, J. M. (2008). Circadian regulation of
response to oxidative stress in Drosophila melanogaster. Biochem. Biophys. Res.
Commun. 374, 299–303. doi: 10.1016/j.bbrc.2008.07.011
Krishnan, N., Kretzschmar, D., Rakshit, K., Chow, E., and Giebultowicz, J. M.
(2009). The circadian clock gene period extends healthspan in aging Drosophila
melanogaster. Aging (Albany NY) 1, 937–948.
Krishnan, N., Rakshit, K., Chow, E. S., Wentzell, J. S., Kretzschmar, D., and
Giebultowicz, J. M. (2012). Loss of circadian clock accelerates aging in
neurodegeneration-prone mutants. Neurobiol. Dis. 45, 1129–1135. doi: 10.1016/
j.nbd.2011.12.034
Kudo, T., Loh, D. H., Truong, D., Wu, Y., and Colwell, C. S. (2011a). Circadian
dysfunction in a mouse model of Parkinson’s disease. Exp. Neurol. 232, 66–75.
doi: 10.1016/j.expneurol.2011.08.003
Kudo, T., Schroeder, A., Loh, D. H., Kuljis, D., Jordan, M. C., Roos, K. P., et al.
(2011b). Dysfunctions in circadian behavior and physiology in mouse models
of Huntington’s disease. Exp. Neurol. 228, 80–90. doi: 10.1016/j.expneurol.
2010.12.011
Kudo, T., Tahara, Y., Gamble, K. L., Mcmahon, D. G., Block, G. D., and Colwell, C.
S. (2013). Vasoactive intestinal peptide produces long-lasting changes in neural
activity in the suprachiasmatic nucleus. J. Neurophysiol. 110, 1097–1106. doi:
10.1152/jn.00114.2013
Laposky, A., Easton, A., Dugovic, C., Walisser, J., Bradfield, C., and Turek, F. (2005).
Deletion of the mammalian circadian clock gene BMAL1/Mop3 alters baseline
sleep architecture and the response to sleep deprivation. Sleep 28, 395–409.
Lim, A. S., Kowgier, M., Yu, L., Buchman, A. S., and Bennett, D. A. (2013a). Sleep
fragmentation and the risk of incident Alzheimer’s disease and cognitive decline
in older persons. Sleep 36, 1027–1032. doi: 10.5665/sleep.2802
Lim, A. S., Myers, A. J., Yu, L., Buchman, A. S., Duffy, J. F., De Jager, P. L.,
et al. (2013b). Sex difference in daily rhythms of clock gene expression in
the aged human cerebral cortex. J. Biol. Rhythms 28, 117–129. doi: 10.1177/
0748730413478552
Lim, A. S., Srivastava, G. P., Yu, L., Chibnik, L. B., Xu, J., Buchman, A. S., et al.
(2014). 24-hour rhythms of DNA methylation and their relation with rhythms
of RNA expression in the human dorsolateral prefrontal cortex. PLoS Genet.
10:e1004792. doi: 10.1371/journal.pgen.1004792
Long, D. M., Blake, M. R., Dutta, S., Holbrook, S. D., Kotwica-Rolinska, J.,
Kretzschmar, D., et al. (2014). Relationships between the circadian system and
Alzheimer’s disease-like symptoms in Drosophila. PLoS ONE 9:e106068. doi:
10.1371/journal.pone.0106068
Maywood, E. S., Fraenkel, E., Mcallister, C. J., Wood, N., Reddy, A. B., Hastings,
M. H., et al. (2010). Disruption of peripheral circadian timekeeping in a
mouse model of Huntington’s disease and its restoration by temporally scheduled feeding. J. Neurosci. 30, 10199–10204. doi: 10.1523/JNEUROSCI.1694-10.
2010
Mohawk, J. A., Green, C. B., and Takahashi, J. S. (2012). Central and peripheral
circadian clocks in mammals. Annu. Rev. Neurosci. 35, 445–462. doi: 10.1146/
annurev-neuro-060909-153128

www.frontiersin.org

Circadian clocks and neurodegeneration

Mongrain, V., La Spada, F., Curie, T., and Franken, P. (2011). Sleep loss reduces
the DNA-binding of BMAL1, CLOCK, and NPAS2 to specific clock genes in
the mouse cerebral cortex. PLoS ONE 6:e26622. doi: 10.1371/journal.pone.
0026622
Morton, A. J., Wood, N. I., Hastings, M. H., Hurelbrink, C., Barker, R. A., and Maywood, E. S. (2005). Disintegration of the sleep–wake cycle and circadian timing
in Huntington’s disease. J. Neurosci. 25, 157–163. doi: 10.1523/JNEUROSCI.
3842-04.2005
Musiek, E. S., Lim, M. M., Yang, G., Bauer, A. Q., Qi, L., Lee, Y., et al. (2013).
Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J. Clin. Invest. 123, 5389–5400. doi: 10.1172/JCI70317
Niwa, F., Kuriyama, N., Nakagawa, M., and Imanishi, J. (2011). Circadian rhythm
of rest activity and autonomic nervous system activity at different stages in
Parkinson’s disease. Auton. Neurosci. 165, 195–200. doi: 10.1016/j.autneu.2011.
07.010
Pallier, P. N., Maywood, E. S., Zheng, Z., Chesham, J. E., Inyushkin, A. N.,
Dyball, R., et al. (2007). Pharmacological imposition of sleep slows cognitive
decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington’s disease. J. Neurosci. 27, 7869–7878. doi:
10.1523/JNEUROSCI.0649-07.2007
Pallier, P. N., and Morton, A. J. (2009). Management of sleep/wake cycles improves
cognitive function in a transgenic mouse model of Huntington’s disease. Brain
Res. 1279, 90–98. doi: 10.1016/j.brainres.2009.03.072
Peter-Derex, L., Yammine, P., Bastuji, H., and Croisile, B. (2014). Sleep and
Alzheimer’s disease. Sleep Med. Rev. 19C, 29–38. doi: 10.1016/j.smrv.2014.
03.007
Rakshit, K., and Giebultowicz, J. M. (2013). Cryptochrome restores dampened
circadian rhythms and promotes healthspan in aging Drosophila. Aging Cell 12,
752–762. doi: 10.1111/acel.12100
Roh, J. H., Huang, Y., Bero, A. W., Kasten, T., Stewart, F. R., Bateman, R. J., et al.
(2012). Disruption of the sleep–wake cycle and diurnal fluctuation of β-amyloid
in mice with Alzheimer’s disease pathology. Sci. Transl. Med. 4, 150ra122. doi:
10.1126/scitranslmed.3004291
Schnell, A., Chappuis, S., Schmutz, I., Brai, E., Ripperger, J. A., Schaad, O., et al.
(2014). The nuclear receptor REV-ERBα regulates Fabp7 and modulates adult
hippocampal neurogenesis. PLoS ONE 9:e99883. doi: 10.1371/journal.pone.
0099883
Skene, D. J., and Swaab, D. F. (2003). Melatonin rhythmicity: effect of age and
Alzheimer’s disease. Exp. Gerontol. 38, 199–206. doi: 10.1016/S0531-5565(02)
00198-5
Spira, A. P., Gamaldo, A. A., An, Y., Wu, M. N., Simonsick, E. M., Bilgel, M., et al.
(2013). Self-reported sleep and β-amyloid deposition in community-dwelling
older adults. JAMA Neurol. 70, 1537–1543. doi: 10.1001/jamaneurol.2013.
4258
Sterniczuk, R., Dyck, R. H., Laferla, F. M., and Antle, M. C. (2010). Characterization
of the 3xTg-AD mouse model of Alzheimer’s disease: part 1. Circadian changes.
Brain Res. 1348, 139–148. doi: 10.1016/j.brainres.2010.05.013
Swaab, D. F., Fliers, E., and Partiman, T. S. (1985). The suprachiasmatic nucleus
of the human brain in relation to sex, age and senile dementia. Brain Res. 342,
37–44. doi: 10.1016/0006-8993(85)91350-2
Tranah, G. J., Blackwell, T., Stone, K. L., Ancoli-Israel, S., Paudel, M. L., Ensrud,
K. E., et al. (2011). Circadian activity rhythms and risk of incident dementia
and mild cognitive impairment in older women. Ann. Neurol. 70, 722–732. doi:
10.1002/ana.22468
Valnegri, P., Khelfaoui, M., Dorseuil, O., Bassani, S., Lagneaux, C., Gianfelice, A.,
et al. (2011). A circadian clock in hippocampus is regulated by interaction
between oligophrenin-1 and Rev-erbα. Nat. Neurosci. 14, 1293–1301. doi:
10.1038/nn.2911
Videnovic, A., and Golombek, D. (2013). Circadian and sleep disorders in
Parkinson’s disease. Exp. Neurol. 243, 45–56. doi: 10.1016/j.expneurol.2012.
08.018
Videnovic, A., Lazar, A. S., Barker, R. A., and Overeem, S. (2014a). ‘The clocks that
time us’-circadian rhythms in neurodegenerative disorders. Nat. Rev. Neurol. 10,
683–693. doi: 10.1038/nrneurol.2014.206
Videnovic, A., Noble, C., Reid, K. J., Peng, J., Turek, F. W., Marconi, A., et al. (2014b).
Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson
disease. JAMA Neurol. 71, 463–469. doi: 10.1001/jamaneurol.2013.6239
Wisor, J. P., Edgar, D. M., Yesavage, J., Ryan, H. S., Mccormick, C. M., Lapustea, N.,
et al. (2005). Sleep and circadian abnormalities in a transgenic mouse model of

February 2015 | Volume 6 | Article 29 | 5

Musiek

Alzheimer’s disease: a role for cholinergic transmission. Neuroscience 131, 375–
385. doi: 10.1016/j.neuroscience.2004.11.018
Witting, W., Kwa, I. H., Eikelenboom, P., Mirmiran, M., and Swaab, D. F. (1990).
Alterations in the circadian rest-activity rhythm in aging and Alzheimer’s
disease. Biol. Psychiatry 27, 563–572. doi: 10.1016/0006-3223(90)90523-5
Wu, Y. H., Fischer, D. F., Kalsbeek, A., Garidou-Boof, M. L., Van Der Vliet, J.,
Van Heijningen, C., et al. (2006). Pineal clock gene oscillation is disturbed in
Alzheimer’s disease, due to functional disconnection from the “master clock.”
FASEB J. 20, 1874–1876. doi: 10.1096/fj.05-4446fje
Yamaguchi, Y., Suzuki, T., Mizoro, Y., Kori, H., Okada, K., Chen, Y., et al. (2013).
Mice genetically deficient in vasopressin V1a and V1b receptors are resistant to
jet lag. Science 342, 85–90. doi: 10.1126/science.1238599
Yang, Y. K., Peng, X. D., Li, Y. H., Wang, Z. R., Chang-Quan, H., Hui, W., et al.
(2013). The polymorphism of CLOCK gene 3111T/C C>T is associated with
susceptibility of Alzheimer disease in Chinese population. J. Investig. Med. 61,
1084–1087. doi: 10.231/JIM.0b013e31829f91c0
Zhang, R., Lahens, N. F., Ballance, H. I., Hughes, M. E., and Hogenesch, J. B. (2014).
A circadian gene expression atlas in mammals: implications for biology and
medicine. Proc. Natl. Acad. Sci. U.S.A. 111, 16219–16224. doi: 10.1073/pnas.
1408886111

Circadian clocks and neurodegeneration

Zhou, J. N., Hofman, M. A., and Swaab, D. F. (1995). VIP neurons in the human
SCN in relation to sex, age, and Alzheimer’s disease. Neurobiol. Aging 16, 571–
576. doi: 10.1016/0197-4580(95)00043-E
Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 20 December 2014; accepted: 03 February 2015; published online:
27 February 2015.
Citation: Musiek ES (2015) Circadian clock disruption in neurodegenerative diseases:
cause and effect? Front. Pharmacol. 6:29. doi: 10.3389/fphar.2015.00029
This article was submitted to Pharmaceutical Medicine and Outcomes Research, a
section of the journal Frontiers in Pharmacology.
Copyright © 2015 Musiek. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.

Frontiers in Pharmacology | Pharmaceutical Medicine and Outcomes Research

February 2015 | Volume 6 | Article 29 | 6

